FINWIRES · TerminalLIVE
FINWIRES

SHE:002317

5 stories mentioning SHE:002317Updated 10d ago

Every FINWIRES story that references SHE:002317, newest first.

Asia

Zhongsheng Pharma Receives China Marketing Application Approval for Antischizophrenic Drug Active Ingredient

Guangdong Zhongsheng Pharmaceutical (SHE:002317) received marketing application approval from China's National Medical Products Administration for its brexpiprazole active pharmaceutical ingredient, according to a Saturday filing with the Shenzhen bourse.The approval allows domestic manufacturing and marketing registration for the product, which is indicated for schizophrenia in adults.Shares rose 2% during afternoon trading on Monday.

SHE:002317
Asia

Zhongsheng Pharmaceutical's Unit Gets Patent From Japan for Polypeptide Drug

Guangdong Zhongsheng Pharmaceutical's (SHE:002317) unit, Guangdong Zhong Sheng Ruichuang Biotechnology, received a patent certificate from Japan's patent regulator for a method for a polypeptide drug, according to a Tuesday disclosure on the Shenzhen bourse.The patent is for the medicinal use of a polypeptide as a treatment and prevention for diabetes, obesity and related diseases.This patent is a core patent covering the company's investigational innovative polypeptide drug RAY1225 Injection.

SHE:002317
Asia

Zhongsheng Pharma's Unit Gets Patent From Japan for the Ketoamide-Inducing Method for Leritrelvir Tablets

Guangdong Zhongsheng Pharmaceutical's (SHE:002317) unit, Guangdong Zhong Sheng Ruichuang Biotechnology, received a patent certificate from Japan for a ketoamide inducing method, according to a Tuesday disclosure on the Shenzhen bourse.The 20-year patent is for the crystal form of a ketoamide derivative and preparation method, which is for the company's oral anti-COVID-19 drug Leritrelvir Tablets, with the brand name Leruiling.Shares of the pharmaceutical company closed 3% higher.

SHE:002317
Asia

Zhongsheng Pharmaceutical's Pediatric Flu Drug Application Accepted

Guangdong Zhongsheng Pharmaceutical (SHE:002317) said China's drug regulator accepted the new drug marketing application for anladwevir granule.The drug is used to treat uncomplicated influenza A in children, according to a Thursday filing with the Shenzhen bourse.

SHE:002317
Asia

Guangdong Zhongsheng Pharmaceutical Gets Marketing Approval for Genital Wart API

Guangdong Zhongsheng Pharmaceutical (SHE:002317) obtained marketing approval for active pharmaceutical ingredient aminolevulinic acid hydrochloride from China's drug administrator.The API is used in preparations treating genital warts, according to a Tuesday filing with the Shenzhen bourse.Shares of the pharmaceutical company were down 3% in recent trade.

SHE:002317

Track with the FINWIRES app suite

FolioX
FolioX
Track SHE:002317 in your portfolio
WheelAI
WheelAI
Analyze SHE:002317 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on SHE:002317